hAb21 / Stainwei Biotech - LARVOL DELTA

"I was refering to hAB21." (@artocarpus44)

Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity. (PubMed, J Hematol Oncol) - "The in vitro and in vivo antitumor activity of hAB21 broadly recapitulates that of CD47 targeted therapies despite differences in ligand expression, binding partners, and function, validating the CD47-SIRPα axis as a fundamental myeloid checkpoint pathway and its blockade as promising therapeutic intervention for treatment of human malignancies."

IO Biomarker • Journal • Immune Modulation • Inflammation • Oncology